Sex Hormone-binding Globulin: A Novel Marker for Nodal Metastases Prediction in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection

Urology

Volumn 73, Issue 4, 2009, Pages 850-855

  Salonia, Andrea ^a   Briganti, Alberto ^a   Gallina, Andrea ^a   Karakiewicz, Pierre ^b   Shariat, Shahrokh ^c   Freschi, Massimo ^a   Zanni, Giuseppe ^a   Capitanio, Umberto ^a   Bosi, Emanuele ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC ACCURACY; DISEASE MARKER; GLEASON SCORE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADICAL RETROPUBIC PROSTATECTOMY;

AGED; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PELVIS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 63149129615     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.09.026     Document Type: Article

References (28)

1. Hricak H., Choyke P.L., Eberhardt S.C., et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 243 (2007) 28-53
2. Allaf M.E., Palapattu G.S., Trock B.J., et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840-1844
3. Briganti A., Chun F.K., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1026
4. Briganti A., Chun F.K., Salonia A., et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50 (2006) 1006-1013
5. Briganti A., Chun F.K., Salonia A., et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 51 (2007) 112-119
6. Gann P.H., Hennekens C.H., Ma J., et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1996) 1118-1126
7. Garcia J.M., Li H., Mann D., et al. Hypogonadism in male patients with cancer. Cancer 106 (2006) 2583-2591
8. Yuen M.T., Leung L.K., Wang J., et al. Enhanced induction of prostatic dysplasia and carcinoma in noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int J Oncol 27 (2005) 1685-1695
9. Usui T., Ishibe T., Nakatsu H., et al. Immunohistochemical localization of testosterone-estradiol-binding globulin in a clinically hormone-independent prostatic carcinoma. Urol Int 38 (1983) 16-18
10. Hryb D.J., Nakhla A.M., Kahn S.M., et al. Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. J Biol Chem 277 (2002) 26618-26622
11. Ojasoo T., Fiet J., Raynaud J.P., et al. A multivariate approach to the description of patient populations: an example of the analysis of the hormone profiles of patients with advanced prostate cancer. J Steroid Biochem Mol Biol 46 (1993) 183-193
12. Grasso M., Buonaguidi A., Mondina R., et al. Plasma sex hormone binding globulin in patients with prostatic carcinoma. Cancer 66 (1990) 354-357
13. Briganti A., Chun F.K., Salonia A., et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 69 (2007) 147-151
14. Pasquali R., Casimirri F., De Iasio R., et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 80 (1995) 654-658
15. National Committee for Clinical Laboratory Standards. How to define, determine, and utilize reference intervals in the clinical laboratory; approved guidelines. NCCLS document C28a (1995), NCCLS, Villanova, PA 59 June
16. Mikkola A.K.K., Aro J.L.V., Rannikko S.A.S., et al. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. Prostate 39 (1999) 175-181
17. Shariat S.F., Kattan M.W., Traxel E., et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10 (2004) 1992-1999
18. Heracek J., Hampl R., Hill M., et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72 (2007) 375-380
19. Heikkilä R., Aho K., Heliövaara M., et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma. Cancer 86 (1999) 312-315
20. Platz E.A., Leitzmann M.F., Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 (2005) 1262-1269
21. Raivio T., Santti H., Schatzl G., et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 55 (2003) 194-198
22. Vermeulen A., Kaufman J.M., and Giagulli V.A. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81 (1996) 1821-1826
23. Damassa D.A., Lin T.M., Sonnenschein C., et al. Biological effects of sex hormone-binding globulin on androgen-induced proliferation and androgen metabolism in LNCaP prostate cells. Endocrinology 129 (1991) 75-84
24. Berndt S.I., Chatterjee N., Huang W.Y., et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 165-168
25. Shariat S.F., Anwuri V.A., Lamb D.J., et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22 (2004) 1655-1663
26. Shariat S.F., Roehrborn C.G., McConnell J.D., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25 (2007) 349-355
27. Blute M.L., Bergstralh E.J., Partin A.W., et al. Validation of parting tables for predicting pathological stage of clinically localized prostate cancer. J Urol 164 (2000) 1591-1595
28. Gapstur S.M., Gann P.H., Kopp P., et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race-the CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 11 (2002) 1041-1047